3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. (September 2015) - Dummer, R.; Sandhu, S.; Hassel, J.C.; Muñoz, E.; Berking, C.; Gesierich, A.; Ascierto, P.A.; Esposito, O.; Carter, K.; Antona, V.; Radhakrishnan, R.; Cui, X.; et al.